| CPC A61K 35/741 (2013.01) [A61K 47/26 (2013.01); A61P 1/04 (2018.01); A61K 2035/115 (2013.01)] | 24 Claims |
|
1. A pharmaceutical composition comprising an effective amount of a bacterial mixture, the mixture comprising an isolated Bacteroides thetaiotaomicron strain, an isolated Eubacterium hallii strain, and an isolated Roseburia hominis strain, and a pharmaceutically acceptable excipient, wherein the bacterial mixture is capable of one or more of
(a) increasing production of IL-10;
(b) increasing production of CCL-18;
(c) increasing gut barrier integrity;
(d) increasing autophagy; and
(e) reducing or attenuating production of plasma Lipocalin-2/NGAL; and
wherein the Bacteroides thetaiotaomicron strain is the live BTH01 (P118-A12a) strain comprising the 16s rRNA sequence of SEQ ID NO: 2; the Eubacterium hallii strain is the live EHA01 (P168-F1a) strain comprising the 16s rRNA sequence of SEQ ID NO: 3; and the Roseburia hominis strain is the live RHO01 (P127-H9a) strain comprising the 16s rRNA sequence of SEQ ID NO: 1, wherein the BTH01 strain is deposited at the DSMZ with the accession number DSM-32919, the EHA01 strain is deposited at the DSMZ with the accession number DSM 32920, and the RHO01 strain is deposited at the DSMZ with the accession number of DSM 32921.
|